Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

HDL – janusartige Assoziation mit kardiovaskulärer Sterblichkeit.

Riesen WF.

Praxis (Bern 1994). 2019;108(7):449. doi: 10.1024/1661-8157/a003245. German. No abstract available.

PMID:
31136270
Free Article
2.

Vitamin D levels in Swiss breast cancer survivors.

Baumann M, Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B.

Swiss Med Wkly. 2018 Jan 16;148:w14576. doi: 10.4414/smw.2018.14576. eCollection 2018.

3.

Independent association of resting energy expenditure with blood pressure: confirmation in populations of the African diaspora.

Creber C, Cooper RS, Plange-Rhule J, Bovet P, Lambert EV, Forrester TE, Schoeller D, Riesen W, Korte W, Cao G, Luke A, Dugas LR.

BMC Cardiovasc Disord. 2018 Jan 10;18(1):4. doi: 10.1186/s12872-017-0737-5.

4.

Lipid-Therapie – warum, für wen und wie intensiv?

Riesen WF.

Praxis (Bern 1994). 2017 Aug;106(17):921-926. doi: 10.1024/1661-8157/a002757. Review. German. No abstract available.

PMID:
28830328
5.

[Inhibitors of PCSK9].

Petrova-Slater I, Denegri A, Pasotti E, Rossi MG, Spirk D, Riesen WF, Moccetti T, Moccetti M.

Rev Med Suisse. 2017 Apr 12;13(558):821-825. French.

6.

Cardiovascular risk status of Afro-origin populations across the spectrum of economic development: findings from the Modeling the Epidemiologic Transition Study.

Dugas LR, Forrester TE, Plange-Rhule J, Bovet P, Lambert EV, Durazo-Arvizu RA, Cao G, Cooper RS, Khatib R, Tonino L, Riesen W, Korte W, Kliethermes S, Luke A.

BMC Public Health. 2017 May 12;17(1):438. doi: 10.1186/s12889-017-4318-4.

7.

The social patterning of risk factors for noncommunicable diseases in five countries: evidence from the modeling the epidemiologic transition study (METS).

Stringhini S, Forrester TE, Plange-Rhule J, Lambert EV, Viswanathan B, Riesen W, Korte W, Levitt N, Tong L, Dugas LR, Shoham D, Durazo-Arvizu RA, Luke A, Bovet P.

BMC Public Health. 2016 Sep 9;16:956. doi: 10.1186/s12889-016-3589-5.

8.

Icosabutate, a More Potent Form of Omega 3 Fatty Acids, Shows Promise in Lowering Triglycerides.

Riesen WF.

Cardiology. 2016;135(1):1-2. doi: 10.1159/000445286. Epub 2016 May 4. No abstract available.

PMID:
27160264
9.

[A new view of arteriosclerosis development points the way to new therapy concepts].

Riesen WF.

Praxis (Bern 1994). 2016 Apr 13;105(8):427. doi: 10.1024/1661-8157/a002325. German. No abstract available.

PMID:
27078724
10.

Toward a more professional and practical medical education: a novel Central European approach.

Drexel H, Vonbank A, Fraunberger P, Riesen WF, Saely CH.

Adv Med Educ Pract. 2015 Jun 23;6:459-67. doi: 10.2147/AMEP.S81016. eCollection 2015.

11.

[Statin treatment in primary and secondary prevention--a statement].

Mach F, Riesen WF, Rodondi N, Von Eckardstein A.

Rev Med Suisse. 2014 Dec 17;10(455):2430-3. French.

PMID:
25752015
12.

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.

Müller-Wieland D, Assmann G, Carmena R, Davignon J, von Eckardstein A, Farinaro E, Greten H, Olsson AG, Riesen WF, Shlyakhto E.

Eur J Prev Cardiol. 2016 Feb;23(3):275-81. doi: 10.1177/2047487314567001. Epub 2015 Jan 16.

PMID:
25595550
13.

[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I, Koenig W, Kostner GM, Landmesser U, Laufs U, Leistikow F, März W, Merkel M, Müller-Wieland D, Noll G, Parhofer KG, Paulweber B, Riesen W, Schaefer JR, Steinhagen-Thiessen E, Steinmetz A, Toplak H, Wanner C, Windler E.

Internist (Berl). 2014 May;55(5):601-6. doi: 10.1007/s00108-014-3492-z. German. Erratum in: Internist (Berl). 2014 Sep;55(9):1112.

PMID:
24770979
14.

New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.

Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I, Heigl F, Koenig W, Kostner GM, Landmesser U, Laufs U, Leistikow F, März W, Noll G, Parhofer KG, Paulweber B, Riesen WF, Schaefer JR, Steinhagen-Thiessen E, Steinmetz A, Toplak H, Wanner C, Windler E; American Heart Association, American College of Cardiology.

Wien Klin Wochenschr. 2014 Mar;126(5-6):169-75. doi: 10.1007/s00508-014-0513-9. Epub 2014 Mar 11.

PMID:
24615676
15.

Low prevalence of abdominal aortic aneurysm in the Seychelles population aged 50 to 65 years.

Yerly P, Madeleine G, Riesen W, Bovet P.

Cardiovasc J Afr. 2013 Mar;24(2):17-8. doi: 10.5830/CVJA-2012-070.

16.

Association between conventional risk factors and different ultrasound-based markers of atherosclerosis at carotid and femoral levels in a middle-aged population.

Yerly P, Rodondi N, Viswanathan B, Riesen W, Vogt P, Bovet P.

Int J Cardiovasc Imaging. 2013 Mar;29(3):589-99. doi: 10.1007/s10554-012-0124-3. Epub 2012 Sep 27.

PMID:
23015308
17.
18.

[New european guidelines for dyslipidemia].

Riesen WF, Virgini V, Vogt B, Rodondi N.

Rev Med Suisse. 2012 Mar 7;8(331):525-6, 528-30. French.

PMID:
22471115
19.

Relation between high-sensitivity C-reactive protein and cardiovascular and renal markers in a middle-income country in the African region.

Rossi IA, Bochud M, Viswanathan B, Riesen W, Bovet P.

Int J Cardiol. 2012 Apr 19;156(2):203-8. doi: 10.1016/j.ijcard.2011.09.084. Epub 2011 Oct 20.

20.

Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial.

Tomonaga Y, Gutzwiller F, Lüscher TF, Riesen WF, Hug M, Diemand A, Schwenkglenks M, Szucs TD.

BMC Fam Pract. 2011 Mar 24;12:12. doi: 10.1186/1471-2296-12-12.

21.

Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.

Joerger M, Templeton A, Köberle D, Engler H, Riesen WF, Thürlimann B.

Cancer Chemother Pharmacol. 2011 May;67(5):1137-44. doi: 10.1007/s00280-010-1420-z. Epub 2010 Aug 4.

PMID:
20683595
22.

Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer.

Joerger M, Riesen WF, Thürlimann B.

J Oncol Pharm Pract. 2011 Sep;17(3):292-4. doi: 10.1177/1078155210378912. Epub 2010 Jul 28.

PMID:
20667851
23.

Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.

Kuster GM, Nietlispach F, Kiowski W, Schindler R, Bernheim A, Schuetz P, Mueller B, Morgenthaler NG, Rüter F, Riesen W, Rickli H, Brunner-La Rocca HP.

Clin Pharmacol Ther. 2010 Jun;87(6):686-92. doi: 10.1038/clpt.2010.36. Epub 2010 May 5.

PMID:
20445533
24.

Commentary to factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis.

Riesen WF.

Atherosclerosis. 2010 Feb;208(2):332-3. doi: 10.1016/j.atherosclerosis.2009.10.038. Epub 2009 Nov 26. No abstract available.

PMID:
20022009
25.

Elevation of the serum total and free prostate-specific antigen levels after stent implantation in patient with coronary artery disease.

Riesen WF.

Swiss Med Wkly. 2009 Nov 14;139(45-46):646. doi: smw-12941. No abstract available.

PMID:
19950030
26.

Divergent fifteen-year trends in traditional and cardiometabolic risk factors of cardiovascular diseases in the Seychelles.

Bovet P, Romain S, Shamlaye C, Mendis S, Darioli R, Riesen W, Tappy L, Paccaud F.

Cardiovasc Diabetol. 2009 Jun 26;8:34. doi: 10.1186/1475-2840-8-34.

27.

Combining bone resorption markers and heel quantitative ultrasound to discriminate between fracture cases and controls.

Nanchen D, Cornuz J, Ruffieux C, Riesen W, Burckhardt P, Krieg MA; SEMOF study group.

Osteoporos Int. 2009 Oct;20(10):1695-703. doi: 10.1007/s00198-009-0843-z. Epub 2009 Jan 31.

PMID:
19184267
28.

[Comment from the lipidologic viewpoint].

Riesen WF.

Praxis (Bern 1994). 2009 Feb 4;98(3):125-7. doi: 10.1024/1661-8157.98.3.125. German. No abstract available.

PMID:
19180437
29.

Relevance of short-term variation of B-type natriuretic peptide in patients with clinically stable heart failure.

Maeder MT, Hack D, Rickli H, Rocca HP, Riesen W, Ammann P.

Wien Klin Wochenschr. 2008;120(21-22):672-8. doi: 10.1007/s00508-008-1099-x.

PMID:
19116708
30.

[Update of lipid lowering therapy].

Riesen WF, Mordasini RC.

Praxis (Bern 1994). 2008 Nov 5;97(22):1179-84. doi: 10.1024/1661-8157.97.22.1179. German.

PMID:
18979436
31.

Metabolic syndrome according to different definitions in a rapidly developing country of the African region.

Kelliny C, William J, Riesen W, Paccaud F, Bovet P.

Cardiovasc Diabetol. 2008 Sep 18;7:27. doi: 10.1186/1475-2840-7-27.

32.
33.

[What are the biomarkers of atherosclerosis and cardiovascular risk?].

Riesen WF.

Rev Med Suisse. 2008 Mar 12;4(148):636-8, 640-3. Review. French.

PMID:
18459658
34.

Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients.

Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, Riesen W, Keller U, Christ E.

Diabetes Care. 2008 Aug;31(8):1534-5. doi: 10.2337/dc08-0385. Epub 2008 Apr 21.

35.

Prevalence of microalbuminuria in the general population of Seychelles and strong association with diabetes and hypertension independent of renal markers.

Pruijm MT, Madeleine G, Riesen WF, Burnier M, Bovet P.

J Hypertens. 2008 May;26(5):871-7. doi: 10.1097/HJH.0b013e3282f624d9.

PMID:
18398328
36.

Heparinized blood provides equivalent results to EDTA in the CEDIA and FPIA cyclosporine immunoassays, thus facilitating routine cyclosporine determination.

Korte WC, Engler H, Aldebert E, Riesen WF.

Clin Chim Acta. 2008 Apr;390(1-2):138-40. doi: 10.1016/j.cca.2007.12.021. Epub 2008 Jan 12.

PMID:
18230354
37.

Cardiopulmonary exercise testing in mild heart failure: impact of the mode of exercise on established prognostic predictors.

Maeder MT, Wolber T, Ammann P, Myers J, Brunner-La Rocca HP, Hack D, Riesen W, Rickli H.

Cardiology. 2008;110(2):135-41. Epub 2007 Oct 31.

38.

Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.

Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hürlimann D, Sudano I, Gay S, Neidhart M, Riesen W, Ruschitzka F, Lüscher TF, Noll G, Lehmann R.

J Hypertens. 2007 Apr;25(4):785-91.

PMID:
17351370
39.

Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults.

Rodondi N, Yerly P, Gabriel A, Riesen WF, Burnier M, Paccaud F, Bovet P.

Nephrol Dial Transplant. 2007 Apr;22(4):1107-14. Epub 2007 Jan 5.

PMID:
17205961
40.

B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure.

Maeder M, Wolber T, Rickli H, Myers J, Hack D, Riesen W, Weilenmann D, Ammann P.

Int J Cardiol. 2007 Sep 3;120(3):391-8. Epub 2006 Dec 19.

PMID:
17182129
41.

N-terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis.

Wolber T, Maeder M, Rickli H, Riesen W, Binggeli C, Duru F, Ammann P.

Eur J Clin Invest. 2007 Jan;37(1):18-25.

PMID:
17181563
42.

Changes in biochemical markers after lower limb fractures.

Stoffel K, Engler H, Kuster M, Riesen W.

Clin Chem. 2007 Jan;53(1):131-4. Epub 2006 Nov 27.

43.

Integration of B-type natriuretic peptide levels with clinical data and exercise testing for predicting coronary artery disease.

Wolber T, Maeder M, Weilenmann D, Duru F, Bluzaite I, Riesen W, Rickli H, Ammann P.

Am J Cardiol. 2006 Sep 15;98(6):764-7. Epub 2006 Jul 28.

PMID:
16950181
44.

Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.

Bovet P, Shamlaye C, Gabriel A, Riesen W, Paccaud F.

BMC Public Health. 2006 Jan 19;6:9.

45.

Economic impact of hyperhomocysteinemia in Switzerland.

Szucs TD, Käser A, Riesen WF.

Cardiovasc Drugs Ther. 2005 Oct;19(5):365-9.

PMID:
16382299
46.

Dark chocolate improves endothelial and platelet function.

Hermann F, Spieker LE, Ruschitzka F, Sudano I, Hermann M, Binggeli C, Lüscher TF, Riesen W, Noll G, Corti R.

Heart. 2006 Jan;92(1):119-20. No abstract available.

47.

Implications of emerging risk factors for therapeutic intervention.

Assmann G, Cullen P, Fruchart JC, Greten H, Naruszewicz M, Olsson A, Paoletti R, Riesen W, Stoll M, Tikkanen M, von Eckardstein A; International Task Force for Prevention of Coronary Heart Disease.

Nutr Metab Cardiovasc Dis. 2005 Oct;15(5):373-81.

PMID:
16216724
48.

Hypertriglyceridemia as a possible risk factor for prostate cancer.

Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, Krek W, Cerny T, Gillessen S.

Prostate Cancer Prostatic Dis. 2005;8(4):316-20.

PMID:
16158078
49.

Preoperative fibrin monomer measurement allows risk stratification for high intraoperative blood loss in elective surgery.

Korte W, Gabi K, Rohner M, Gähler A, Szadkowski C, Schnider TW, Lange J, Riesen W.

Thromb Haemost. 2005 Jul;94(1):211-5.

PMID:
16113806
50.

[Protective effects of pravastatin against atherosclerosis in children with familial hypercholesterolemia].

Riesen WF.

Rev Med Suisse. 2005 Mar 2;1(9):649. French. No abstract available.

PMID:
15813344

Supplemental Content

Loading ...
Support Center